
Roche’s Vabysmo Proves Durable and Effective in Long-Term DME Study
Roche announced new, four-year data from the RHONE-X extension study today. The study met all primary endpoints, demonstrating that Vabysmo® (faricimab) was well tolerated in people with diabetic macular edema…













